;PMID: 10754986
;source_file_738.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..32] = [t:0..32]
;1)sentence:[e:37..153] = [t:37..153]
;2)section:[e:157..256] = [t:157..256]
;3)section:[e:260..299] = [t:260..299]
;4)sentence:[e:303..446] = [t:303..446]
;5)sentence:[e:447..582] = [t:447..582]
;6)sentence:[e:583..698] = [t:583..698]
;7)sentence:[e:700..805] = [t:700..805]
;8)sentence:[e:806..891] = [t:806..891]
;9)sentence:[e:892..1094] = [t:892..1094]
;10)sentence:[e:1095..1199] = [t:1095..1199]
;11)sentence:[e:1200..1264] = [t:1200..1264]
;12)sentence:[e:1265..1391] = [t:1265..1391]
;13)sentence:[e:1392..1494] = [t:1392..1494]
;14)sentence:[e:1496..1643] = [t:1496..1643]
;15)sentence:[e:1644..1731] = [t:1644..1731]
;16)section:[e:1735..1753] = [t:1735..1753]
;17)section:[e:1755..1769] = [t:1755..1769]
;18)section:[e:1773..1818] = [t:1773..1818]

;section 0 Span:0..32
;Cancer Invest  2000;18(3):185-90
(SEC
  (FRAG (NN:[0..6] Cancer) (NNP:[7..13] Invest) (CD:[15..19] 2000)
        (CC:[19..23] ;18-LRB-) (CD:[23..24] 3) (-RRB-:[24..25] -RRB-)
        (CD:[25..29] :185) (::[29..30] -) (CD:[30..32] 90)))

;sentence 1 Span:37..153
;Prognostic role of K-ras in patients with progressive colon cancer who
;received  treatment with Marimastat (BB2516).
;[56..61]:gene-rna:"K-ras"
;[79..103]:malignancy:"progressive colon cancer"
(SENT
  (NP-HLN
    (NP (JJ:[37..47] Prognostic) (NN:[48..52] role))
    (PP (IN:[53..55] of)
      (NP (NN:[56..61] K-ras)))
    (PP-LOC (IN:[62..64] in)
      (NP
        (NP
          (NP (NNS:[65..73] patients))
          (PP (IN:[74..78] with)
            (NP (JJ:[79..90] progressive) (NN:[91..96] colon)
                (NN:[97..103] cancer))))
        (SBAR
          (WHNP-1 (WP:[104..107] who))
          (S
            (NP-SBJ-1 (-NONE-:[107..107] *T*))
            (VP (VBD:[108..116] received)
              (NP
                (NP (NN:[118..127] treatment))
                (PP (IN:[128..132] with)
                  (NP (NN:[133..143] Marimastat)
                    (PRN (-LRB-:[144..145] -LRB-)
                      (NP (NN:[145..151] BB2516))
                      (-RRB-:[151..152] -RRB-))))))))))
    (.:[152..153] .)))

;section 2 Span:157..256
;Nemunaitis J, Cox J, Hays S, Meyer W, Kebart R, Ognoskie N, Courtney A, Yu Y,
; Rasmussen H, Tong A.
(SEC
  (S (NNP:[157..167] Nemunaitis) (NNP:[168..170] J,) (NNP:[171..174] Cox)
     (NNP:[175..177] J,) (NNP:[178..182] Hays) (NNP:[183..185] S,)
     (NNP:[186..191] Meyer) (NNP:[192..193] W) (,:[193..194] ,)
     (NNP:[195..201] Kebart) (NNP:[202..204] R,) (NNP:[205..213] Ognoskie)
     (NNP:[214..215] N) (,:[215..216] ,) (NNP:[217..225] Courtney)
     (NNP:[226..227] A) (,:[227..228] ,) (NNP:[229..231] Yu) (NNP:[232..233] Y)
     (,:[233..234] ,) (NNP:[236..245] Rasmussen) (NNP:[246..247] H)
     (,:[247..248] ,) (NNP:[249..253] Tong) (NN:[254..256] A.)))

;section 3 Span:260..299
;PRN Research, Inc., Dallas, Texas, USA.
(SEC
  (FRAG (NNP:[260..263] PRN) (NNP:[264..272] Research) (,:[272..273] ,)
        (NNP:[274..278] Inc.) (,:[278..279] ,) (NNP:[280..286] Dallas)
        (,:[286..287] ,) (NNP:[288..293] Texas) (,:[293..294] ,)
        (NNP:[295..298] USA) (.:[298..299] .)))

;sentence 4 Span:303..446
;We determined the prognostic role of K-ras mutation in tumor tissue of
;patients  with refractory colon cancer who received Marimastat (BB2516).
;[340..345]:gene-rna:"K-ras"
;[358..370]:malignancy:"tumor tissue"
;[389..412]:malignancy:"refractory colon cancer"
(SENT
  (S
    (NP-SBJ (PRP:[303..305] We))
    (VP (VBD:[306..316] determined)
      (NP
        (NP (DT:[317..320] the) (JJ:[321..331] prognostic) (NN:[332..336] role))
        (PP (IN:[337..339] of)
          (NP (NN:[340..345] K-ras) (NN:[346..354] mutation))))
      (PP-LOC (IN:[355..357] in)
        (NP
          (NP (NN:[358..363] tumor) (NN:[364..370] tissue))
          (PP (IN:[371..373] of)
            (NP
              (NP
                (NP (NNS:[374..382] patients))
                (PP (IN:[384..388] with)
                  (NP (JJ:[389..399] refractory) (NN:[400..405] colon)
                      (NN:[406..412] cancer))))
              (SBAR
                (WHNP-1 (WP:[413..416] who))
                (S
                  (NP-SBJ-1 (-NONE-:[416..416] *T*))
                  (VP (VBD:[417..425] received)
                    (NP (NN:[426..436] Marimastat)
                      (PRN (-LRB-:[437..438] -LRB-)
                        (NP (NN:[438..444] BB2516))
                        (-RRB-:[444..445] -RRB-)))))))))))
    (.:[445..446] .)))

;sentence 5 Span:447..582
;DNA was extracted  from paraffin-stored tumor tissue of 27 patients who
;previously failed  5-fluorouracil and were treated with BB2516.
;[487..499]:malignancy:"tumor tissue"
(SENT
  (S
    (NP-SBJ-2 (NN:[447..450] DNA))
    (VP (VBD:[451..454] was)
      (VP (VBN:[455..464] extracted)
        (NP-2 (-NONE-:[464..464] *))
        (PP (IN:[466..470] from)
          (NP
            (NP
              (ADJP (NN:[471..479] paraffin) (HYPH:[479..480] -)
                    (VBN:[480..486] stored))
               (NN:[487..492] tumor) (NN:[493..499] tissue))
            (PP (IN:[500..502] of)
              (NP
                (NP (CD:[503..505] 27) (NNS:[506..514] patients))
                (SBAR
                  (WHNP-1 (WP:[515..518] who))
                  (S
                    (NP-SBJ-1 (-NONE-:[518..518] *T*))
                    (ADVP-TMP (RB:[519..529] previously))
                    (VP
                      (VP (VBD:[530..536] failed)
                        (NP (NN:[538..552] 5-fluorouracil)))
                      (CC:[553..556] and)
                      (VP (VBD:[557..561] were)
                        (VP (VBN:[562..569] treated)
                          (NP-1 (-NONE-:[569..569] *))
                          (PP-CLR (IN:[570..574] with)
                            (NP (NN:[575..581] BB2516))))))))))))))
    (.:[581..582] .)))

;sentence 6 Span:583..698
;The presence of K-ras mutation was  characterized by Polymerase Chain
;Reaction using ras- and p53-specific primers.
;[599..604]:gene-rna:"K-ras"
;[636..646]:gene-protein:"Polymerase"
;[668..671]:gene-rna:"ras"
;[677..680]:gene-rna:"p53"
(SENT
  (S
    (NP-SBJ-3
      (NP (DT:[583..586] The) (NN:[587..595] presence))
      (PP (IN:[596..598] of)
        (NP (NN:[599..604] K-ras) (NN:[605..613] mutation))))
    (VP (VBD:[614..617] was)
      (VP (VBN:[619..632] characterized)
        (NP-3 (-NONE-:[632..632] *))
        (PP-MNR (IN:[633..635] by)
          (NP (NN:[636..646] Polymerase) (NN:[647..652] Chain)
              (NN:[653..661] Reaction)))
        (S-ADV
          (NP-SBJ (-NONE-:[661..661] *))
          (VP (VBG:[662..667] using)
            (NP
              (NP
                (NML (NN:[668..671] ras) (HYPH:[671..672] -)
                  (ADJP-2 (-NONE-:[672..672] *P*)))
                (NML-1 (-NONE-:[672..672] *P*)))
              (CC:[673..676] and)
              (NP
                (ADJP (NN:[677..680] p53) (HYPH:[680..681] -)
                  (ADJP-2 (JJ:[681..689] specific)))
                (NML-1 (NNS:[690..697] primers))))))))
    (.:[697..698] .)))

;sentence 7 Span:700..805
;ras and p53 oncoprotein expression was analyzed by an automated biotin-avidin
; immunoproxidase technique.
;[700..703]:gene-protein:"ras"
;[708..711]:gene-protein:"p53"
;[771..777]:gene-protein:"avidin"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[700..703] ras)
        (NML-1 (-NONE-:[703..703] *P*)))
      (CC:[704..707] and)
      (NP (NN:[708..711] p53)
        (NML-1 (NN:[712..723] oncoprotein) (NN:[724..734] expression))))
    (VP (VBD:[735..738] was)
      (VP (VBN:[739..747] analyzed)
        (NP-2 (-NONE-:[747..747] *))
        (PP-MNR (IN:[748..750] by)
          (NP (DT:[751..753] an) (VBN:[754..763] automated)
            (NML (NN:[764..770] biotin) (HYPH:[770..771] -)
                 (NN:[771..777] avidin))
            (NN:[779..794] immunoproxidase) (NN:[795..804] technique)))))
    (.:[804..805] .)))

;sentence 8 Span:806..891
;Seventeen patients had a normal K-ras sequence and 10  patients had a K-ras
;mutation.
;[838..843]:gene-rna:"K-ras"
;[876..881]:gene-rna:"K-ras"
(SENT
  (S
    (S
      (NP-SBJ (CD:[806..815] Seventeen) (NNS:[816..824] patients))
      (VP (VBD:[825..828] had)
        (NP (DT:[829..830] a) (JJ:[831..837] normal) (NN:[838..843] K-ras)
            (NN:[844..852] sequence))))
    (CC:[853..856] and)
    (S
      (NP-SBJ (CD:[857..859] 10) (NNS:[861..869] patients))
      (VP (VBD:[870..873] had)
        (NP (DT:[874..875] a) (NN:[876..881] K-ras) (NN:[882..890] mutation))))
    (.:[890..891] .)))

;sentence 9 Span:892..1094
;Median survival of patients with a normal ras  sequence was 330 days from the
;time of BB2516 treatment compared with 160 days  for patients with a K-ras
;mutation (p = 0.0442, Wilcoxon; 0.0130 Log-Rank).
;[934..937]:gene-rna:"ras"
;[1039..1044]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[892..898] Median) (NN:[899..907] survival))
      (PP (IN:[908..910] of)
        (NP
          (NP (NNS:[911..919] patients))
          (PP (IN:[920..924] with)
            (NP (DT:[925..926] a) (JJ:[927..933] normal) (NN:[934..937] ras)
                (NN:[939..947] sequence))))))
    (VP (VBD:[948..951] was)
      (NP-PRD
        (NP
          (NP (CD:[952..955] 330) (NNS:[956..960] days))
          (PP (IN:[961..965] from)
            (NP
              (NP (DT:[966..969] the) (NN:[970..974] time))
              (PP (IN:[975..977] of)
                (NP (NN:[978..984] BB2516) (NN:[985..994] treatment))))))
        (VP (VBN:[995..1003] compared)
          (NP (-NONE-:[1003..1003] *))
          (PP (IN:[1004..1008] with)
            (NP
              (NP (CD:[1009..1012] 160) (NNS:[1013..1017] days))
              (PP (IN:[1019..1022] for)
                (NP
                  (NP (NNS:[1023..1031] patients))
                  (PP (IN:[1032..1036] with)
                    (NP (DT:[1037..1038] a) (NN:[1039..1044] K-ras)
                        (NN:[1045..1053] mutation)
                      (PRN (-LRB-:[1054..1055] -LRB-)
                        (FRAG
                          (S
                            (NP-SBJ (NN:[1055..1056] p))
                            (VP (SYM:[1057..1058] =)
                              (NP (CD:[1059..1065] 0.0442))))
                          (,:[1065..1066] ,)
                          (NP (NNP:[1067..1075] Wilcoxon))
                          (::[1075..1076] ;)
                          (NP (CD:[1077..1083] 0.0130) (NNP:[1084..1087] Log)
                              (HYPH:[1087..1088] -) (NNP:[1088..1092] Rank)))
                        (-RRB-:[1092..1093] -RRB-)))))))))))
    (.:[1093..1094] .)))

;sentence 10 Span:1095..1199
;No  differences in age, sex, cancer stage, surgical treatment, or
;chemotherapy  treatment were observed.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1095..1097] No) (NNS:[1099..1110] differences))
      (PP (IN:[1111..1113] in)
        (NP
          (NP (NN:[1114..1117] age))
          (,:[1117..1118] ,)
          (NP (NN:[1119..1122] sex))
          (,:[1122..1123] ,)
          (NP (NN:[1124..1130] cancer) (NN:[1131..1136] stage))
          (,:[1136..1137] ,)
          (NP (JJ:[1138..1146] surgical) (NN:[1147..1156] treatment))
          (,:[1156..1157] ,) (CC:[1158..1160] or)
          (NP (NN:[1161..1173] chemotherapy) (NN:[1175..1184] treatment)))))
    (VP (VBD:[1185..1189] were)
      (VP (VBN:[1190..1198] observed)
        (NP-1 (-NONE-:[1198..1198] *))))
    (.:[1198..1199] .)))

;sentence 11 Span:1200..1264
;Abnormalities involving ras expression did not affect  survival.
;[1224..1227]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1200..1213] Abnormalities))
      (VP (VBG:[1214..1223] involving)
        (NP (NN:[1224..1227] ras) (NN:[1228..1238] expression))))
    (VP (VBD:[1239..1242] did) (RB:[1243..1246] not)
      (VP (VB:[1247..1253] affect)
        (NP (NN:[1255..1263] survival))))
    (.:[1263..1264] .)))

;sentence 12 Span:1265..1391
;By comparison, median survival for patients with p53 mutation or p53 
;overexpression was both 158 days after BB2516 treatment.
;[1314..1317]:gene-rna:"p53"
;[1330..1333]:gene-rna:"p53"
(SENT
  (S
    (PP (IN:[1265..1267] By)
      (NP (NN:[1268..1278] comparison)))
    (,:[1278..1279] ,)
    (NP-SBJ
      (NP (JJ:[1280..1286] median) (NN:[1287..1295] survival))
      (PP (IN:[1296..1299] for)
        (NP
          (NP (NNS:[1300..1308] patients))
          (PP (IN:[1309..1313] with)
            (NP
              (NP (NN:[1314..1317] p53) (NN:[1318..1326] mutation))
              (CC:[1327..1329] or)
              (NP (NN:[1330..1333] p53) (NN:[1335..1349] overexpression)))))))
    (VP (VBD:[1350..1353] was) (DT:[1354..1358] both)
      (NP-PRD
        (NP (CD:[1359..1362] 158) (NNS:[1363..1367] days))
        (PP-TMP (IN:[1368..1373] after)
          (NP (NN:[1374..1380] BB2516) (NN:[1381..1390] treatment)))))
    (.:[1390..1391] .)))

;sentence 13 Span:1392..1494
;Patients having both  K-ras and p53 mutations had the poorest median survival
;of 113 days (p = 0.035).
;[1414..1419]:gene-rna:"K-ras"
;[1424..1427]:gene-rna:"p53"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1392..1400] Patients))
      (VP (VBG:[1401..1407] having)
        (NP (CC:[1408..1412] both)
          (NP (NN:[1414..1419] K-ras)
            (NML-1 (-NONE-:[1419..1419] *P*)))
          (CC:[1420..1423] and)
          (NP (NN:[1424..1427] p53)
            (NML-1 (NNS:[1428..1437] mutations))))))
    (VP (VBD:[1438..1441] had)
      (NP
        (NP (DT:[1442..1445] the) (JJS:[1446..1453] poorest)
            (JJ:[1454..1460] median) (NN:[1461..1469] survival))
        (PP (IN:[1470..1472] of)
          (NP (CD:[1473..1476] 113) (NNS:[1477..1481] days)
            (PRN (-LRB-:[1482..1483] -LRB-)
              (S
                (NP-SBJ (NN:[1483..1484] p))
                (VP (SYM:[1485..1486] =)
                  (NP (CD:[1487..1492] 0.035))))
              (-RRB-:[1492..1493] -RRB-))))))
    (.:[1493..1494] .)))

;sentence 14 Span:1496..1643
;There is a suggestion by univariate analysis that the presence of a K-ras 
;mutation may predict survival in patients with progressive colon cancer.
;[1564..1569]:gene-rna:"K-ras"
;[1618..1642]:malignancy:"progressive colon cancer"
(SENT
  (S
    (NP-SBJ (EX:[1496..1501] There))
    (VP (VBZ:[1502..1504] is)
      (NP-PRD
        (NP (DT:[1505..1506] a) (NN:[1507..1517] suggestion)
          (SBAR-1 (-NONE-:[1517..1517] *ICH*)))
        (PP (IN:[1518..1520] by)
          (NP (JJ:[1521..1531] univariate) (NN:[1532..1540] analysis)))
        (SBAR-1 (IN:[1541..1545] that)
          (S
            (NP-SBJ
              (NP (DT:[1546..1549] the) (NN:[1550..1558] presence))
              (PP (IN:[1559..1561] of)
                (NP (DT:[1562..1563] a) (NN:[1564..1569] K-ras)
                    (NN:[1571..1579] mutation))))
            (VP (MD:[1580..1583] may)
              (VP (VB:[1584..1591] predict)
                (NP (NN:[1592..1600] survival))
                (PP-LOC (IN:[1601..1603] in)
                  (NP
                    (NP (NNS:[1604..1612] patients))
                    (PP (IN:[1613..1617] with)
                      (NP (JJ:[1618..1629] progressive) (NN:[1630..1635] colon)
                          (NN:[1636..1642] cancer)))))))))))
    (.:[1642..1643] .)))

;sentence 15 Span:1644..1731
;Further  assessment with larger patient numbers and multivariate analysis is
;indicated.
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1644..1651] Further) (NN:[1653..1663] assessment))
      (PP (IN:[1664..1668] with)
        (NP
          (NP (JJR:[1669..1675] larger) (NN:[1676..1683] patient)
              (NNS:[1684..1691] numbers))
          (CC:[1692..1695] and)
          (NP (JJ:[1696..1708] multivariate) (NN:[1709..1717] analysis)))))
    (VP (VBZ:[1718..1720] is)
      (VP (VBN:[1721..1730] indicated)
        (NP-1 (-NONE-:[1730..1730] *))))
    (.:[1730..1731] .)))

;section 16 Span:1735..1753
;Publication Types:
(SEC
  (FRAG (NNP:[1735..1746] Publication) (NNP:[1747..1752] Types)
        (::[1752..1753] :)))

;section 17 Span:1755..1769
;Clinical Trial
(SEC
  (FRAG (NNP:[1755..1763] Clinical) (NNP:[1764..1769] Trial)))

;section 18 Span:1773..1818
;PMID: 10754986 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1773..1777] PMID) (::[1777..1778] :) (CD:[1779..1787] 10754986)
        (NN:[1788..1789] -LSB-) (NNP:[1789..1795] PubMed) (::[1796..1797] -)
        (NN:[1798..1805] indexed) (IN:[1806..1809] for)
        (NNP:[1810..1818] MEDLINE-RSB-)))
